Login / Signup

18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy.

Gaurav MalviyaRachana PatelMark SaljiRafael S MartinezPeter RepiscakErnest MuiSusan ChampionAgata MrowinskaEmma JohnsonMaha AlRasheediSally PimlottDavid LewisHing Y Leung
Published in: EJNMMI research (2020)
We studied in vivo 18F-Fluciclovine uptake in human prostate cancer orthograft models following acute and chronic ADT. 18F-Fluciclovine uptakes highlight tumour heterogeneity that may explain castration resistance and can be exploited as a clinical biomarker.
Keyphrases